Avantium intends to list on Euronext Amsterdam

Avantium has announced its intention to raise new funds through an IPO and to apply for a listing on Eurolist by Euronext Amsterdam before the end of the year, subject to market conditions.

Avantium, a spin-off from Royal Dutch Shell in 2000, has developed advanced proprietary high-throughput R&D technology.

This enables it to conduct many automated experiments in parallel on a very small scale, providing fast and cost effective research at superior success rates.

Avantium provides R&D services and tools to more than 70 companies worldwide across the energy, chemicals and pharmaceutical industries including BP, Royal Dutch Shell, Sasol, Pfizer, Boehringer Ingelheim and GlaxoSmithKline.

Funds raised through an IPO will be used to further grow the business by advancing product development in the fields of next generation biofuels and improved forms of existing drugs.

Avantium also announced today breakthrough results of the first engine tests of its novel next generation biofuel with superior economics and properties compared to current biofuels.

Avantium International B.V.

Avantium International B.V.
R&D services